1543P - Clinical study of camrelizumab combined with docetaxel and carboplatin in neoadjuvant treatment of locally advanced oesophageal squamous cell carcinoma

Background

Immunotherapy is effective in treating unresectable oesophageal squamous cell carcinoma (ESCC). This study aims to evaluate the clinical efficacy and safety of neoadjuvant camrelizumab combined with docetaxel and carboplatin in locally advanced ESCC.

Methods

All patients underwent surgery within 4-8 weeks after receiving 2 cycles of neoadjuvant therapy, which was camrelizumab (200mg IV Q3W) combined with docetaxel (75 mg/m² IV Q3W) and carboplatin (AUC= 5-6 IV Q3W). The pathological complete response (pCR) rate was the primary endpoint, and the secondary endpoints included R0 resection rate, objective response rate (ORR), disease-free survival (DFS), overall survival (OS) and safety.

Results

A total of 40 patients were included, of which 37 patients were evaluated, including 9 cases of complete response (CR), 18 cases of partial response (PR), 10 cases of stable disease (SD), and the ORR was 73% (27/37). The main adverse events were ALT/AST increase 52.5% (21/40), leukopenia 50% (20/40), nausea and vomiting 47.5% (19/40), bilirubin increase 40% (16/40), all of which were grade 1-2. One patient had Guillain-Barre Syndrome. Among these patients, 31 underwent surgical treatment, pCR rate was 22.6% (7/31), R0 resection rate was 100% (31/31), tumour regression grade (TRG) 0, 1, 2 and 3 were 22.6% (7/31), 16.1% (5/31), 22.6% (7/31) and 38.7% (12/31), respectively. The average operation time (310.0±57.6 minutes). The average intraoperative blood loss (136.1±41.4 ml) and the average hospitalization time after operation (10.9±2.7 days). The average number of resected lymph nodes (24.4±8.2). Surgery-related complications: anastomotic leakage 6.5% (2/31), pleural effusion 6.5% (2/31), cardiac arrhythmia 9.7% (3/31), pneumonia 3.2% (1/31), gastric emptying disorder 3.2% (1/31). The median follow-up time was 12 months (range 1–32 months). One patient had liver metastasis 21 months after surgery. No treatment-related death occurred.

Conclusions

Camrelizumab combined with docetaxel and carboplatin is effective and safe in the neoadjuvant treatment of locally advanced ESCC.

Clinical trial identification

ChiCTR2000033252.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.